Menlo proposes $97.8M IPO

Menlo Therapeutics Inc. (Menlo Park, Calif.) proposed to raise up to $97.8 million in an IPO on NASDAQ, according to an SEC filing on Dec. 28, 2017. Jefferies, Piper Jaffray, Guggenheim and JMP Securities are underwriting the offering.

This half, Menlo plans to start two Phase III trials of lead candidate serlopitant (VPD-737) to treat pruritus associated with prurigo nodularis. The product is a small molecule neurokinin 1 receptor (NK1R; TACR1) antagonist...